CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma

BACKGROUND: The emergence of immune checkpoint inhibitors (ICIs) marks the beginning of a new era of immunotherapy for hepatocellular carcinoma (HCC), however, not all patients respond successfully to this treatment. A major challenge for HCC immunotherapy is the development of ways to screen for th...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Lin, Zhou, Qiaodan, Liu, Junjie, Zhang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581472/
https://www.ncbi.nlm.nih.gov/pubmed/34777372
http://dx.doi.org/10.3389/fimmu.2021.759565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581472/
https://www.ncbi.nlm.nih.gov/pubmed/34777372
http://dx.doi.org/10.3389/fimmu.2021.759565

Ejemplares similares